Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
This study has been completed.
Sponsor:
Dr. Reddy's Laboratories Limited
Information provided by:
Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier:
NCT01314352
First received: March 11, 2011
Last updated: June 7, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex® 5 mg tablet in healthy subjects under fed conditions.
| Condition | Intervention | Phase |
|---|---|---|
|
Fed |
Drug: Desloratadine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-availability Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions |
Resource links provided by NLM:
MedlinePlus related topics:
Malnutrition
Drug Information available for:
Desloratadine
U.S. FDA Resources
Further study details as provided by Dr. Reddy's Laboratories Limited:
Primary Outcome Measures:
- Bioavailability is based on Cmax and AUC parameters [ Time Frame: 4 months ] [ Designated as safety issue: No ]
| Enrollment: | 28 |
| Study Start Date: | December 2005 |
| Study Completion Date: | March 2006 |
| Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Desloratadine Tablets, 5 mg
Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
|
Drug: Desloratadine
Desloratadine Tablets, 5 mg
Other Name: Clarinex® 5 mg
|
|
Active Comparator: Clarinex
Clarinex® 5 mg Tablets of Schering-Plough
|
Drug: Desloratadine
Desloratadine Tablets, 5 mg
Other Name: Clarinex® 5 mg
|
Detailed Description:
A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in fed Normal,Healthy subjects.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Is the individual a healthy, normal adult man and women who volunteers to participate?
- Is s/he within 18 and 45 years of age, inclusive?
- Is his/her BMI between 19 and 30, inclusive?
- Is she willing to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the study?
- Is s/he considered reliable and capable of understanding his/her responsibility and role in the study?
- Has s/he provided written informed consent?
A no answer to any of the above questions indicates that the individual is ineligible for enrollment
Exclusion Criteria:
Does the individual have a history of allergy or hypersensitivity to desloratadine?
- Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- Is she nursing?
- Does s/he have serious psychological illness?
- Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
- Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test?
- Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period? .
- Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
- Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
- Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
- Has s/he donated plasma during the two week period preceding study initiation?
- Has s/he used any tobacco products in the 3 months preceding drug administration?
- Has s/he received an investigational drug during the 30 day period preceding study initiation? A yes answer to any of the above questions indicates that the individual is ineligible for enrollment.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314352
Locations
| United States, Florida | |
| SFBC, Ft. Myers, Inc., | |
| Ft. Myers, Florida, United States, 33901 | |
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
| Principal Investigator: | Antonio R. Pizarro, M.D., | SFBC Ft. Myers, Inc |
More Information
No publications provided
| Responsible Party: | Dr. M.S. Mohan/Vice President - R&D, Dr. Reddy's Laboratories Limited |
| ClinicalTrials.gov Identifier: | NCT01314352 History of Changes |
| Other Study ID Numbers: | 50486 |
| Study First Received: | March 11, 2011 |
| Last Updated: | June 7, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Desloratadine Loratadine Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
Histamine H1 Antagonists, Non-Sedating Histamine H1 Antagonists Histamine Antagonists Histamine Agents Antipruritics Dermatologic Agents Therapeutic Uses Anti-Allergic Agents |
ClinicalTrials.gov processed this record on June 17, 2013